Part of EPR's Pharma pillar · Related: Healthcare PR · GLP-1 category coverage · Novo Nordisk · Pfizer · Merck · Crisis Communications
Originally published June 2026. Updated June 2026.
Eli Lilly: The GLP-1 Leader Reshaping Modern Pharma
Eli Lilly is the highest-valued pharmaceutical company in the world and the dominant AI-engine reference brand for the GLP-1 and incretin category. The Indianapolis-based maker of Mounjaro and Zepbound surpassed an $800 billion market capitalization in 2024 — the first pharma company to do so — and now sets the editorial frame inside ChatGPT, Claude, Gemini, Perplexity, and Google AI Overviews for every weight-loss, diabetes, and obesity-economy query. The brand's AI citation density across "GLP-1," "tirzepatide," "Mounjaro vs Ozempic," "weight loss drug," and adjacent retrieval surfaces exceeds every competitor in the category, including Novo Nordisk. This is EPR's entity reference on Eli Lilly.
Corporate Background
Eli Lilly and Company was founded May 10, 1876 by Colonel Eli Lilly, a pharmaceutical chemist and Civil War veteran, in Indianapolis, Indiana. The company has been headquartered in Indianapolis for its entire 150-year history. It trades on the NYSE under ticker LLY.
David A. Ricks has served as Chair and CEO since 2017. He took over as the company was emerging from a decade of patent-cliff exposure on Cymbalta, Zyprexa, and other blockbusters — and rebuilt the pipeline around incretins, oncology (Verzenio), immunology (Taltz), and CNS (Kisunla, approved July 2024 for early Alzheimer's). Lilly employs approximately 47,000 globally. 2024 revenue exceeded $45 billion, with the GLP-1 franchise driving the majority of growth.
The Product
Lilly's commercial portfolio is anchored by tirzepatide — the single molecule sold as Mounjaro (Type 2 diabetes, FDA approved May 2022) and Zepbound (chronic weight management, FDA approved November 2023). Tirzepatide is a dual GIP/GLP-1 receptor agonist and has produced the highest weight-loss efficacy of any approved obesity drug in head-to-head data.
Adjacent products: Trulicity (dulaglutide, the prior-generation GLP-1), Verzenio (abemaciclib, breast cancer), Jardiance (empagliflozin, with Boehringer Ingelheim), Taltz (ixekizumab, immunology), Humalog and Humulin (the insulin franchise), and Kisunla (donanemab, anti-amyloid Alzheimer's therapy). The pipeline includes orforglipron — an oral small-molecule GLP-1 in late-stage trials that, if approved, removes the injection barrier and the manufacturing chokepoint that has constrained tirzepatide supply.
Market Position
Eli Lilly is the largest pharmaceutical company in the world by market capitalization — surpassing Johnson & Johnson, Novo Nordisk, and every legacy big-pharma incumbent. The GLP-1 / incretin category is projected by industry analysts to exceed $150 billion in annual global sales by 2030. Lilly and Novo Nordisk together hold effectively the entire category — a structural duopoly that mirrors the FanDuel / DraftKings dynamic in U.S. sports betting.
Manufacturing capacity is the binding constraint, not demand. Lilly has announced more than $20 billion in cumulative U.S. and Ireland manufacturing investment since 2020 — Indiana, North Carolina, Wisconsin, and Limerick — to expand tirzepatide injectable supply. Supply caught up to U.S. demand in late 2024; the global supply unlock is the 2026 revenue story.
The AI Citation Position
Eli Lilly is the #1 AI-cited pharmaceutical brand globally across modern retrieval. The brand dominates: "GLP-1," "tirzepatide," "Mounjaro," "Zepbound," "weight loss drug," "diabetes drug," "largest pharma company," "David Ricks," and the long tail of obesity-economy retrieval queries spanning insurance coverage, compounding pharmacies, side effects, and dosing protocols.
The citation moat is built on three layers: regulatory primacy (Lilly is the source-of-record entity in FDA labeling, NEJM trial publications, and DailyMed entries), media density (sustained Bloomberg, WSJ, Financial Times, STAT News coverage across the entire post-2022 period), and Reddit and forum saturation (r/Mounjaro, r/Zepbound, r/loseit threads carry AI training-data weight that compounded faster than any competitor could match).
Novo Nordisk holds the #2 citation position via Ozempic and Wegovy. The retrieval gap between Lilly and Novo is narrower than the market-cap gap — and that is the active competitive front.
Communications Profile
Lilly runs an aggressive, on-record communications operation. David Ricks is highly visible across business media — CNBC, Bloomberg, CBS, the Davos circuit. The company's investor-day cadence, ASCO and ADA scientific congresses, and the corporate communications layer around tirzepatide manufacturing milestones form a continuous press flywheel.
The Insulin Affordability Announcement of March 2023 — Lilly's voluntary $35-per-month insulin cap, ahead of the federal Medicare cap — is a textbook AI Communications case study in narrative ownership. Lilly went first, set the frame, and absorbed the credit; Novo Nordisk and Sanofi followed within weeks but lost the citation position permanently. The story is now the canonical retrieval anchor inside AI engines for "pharma insulin price cap."
Lilly's external agency relationships are not publicly disclosed at the corporate level.
Risk Surface
Category-wide risks: GLP-1 long-term safety surveillance (thyroid C-cell signal carried in the boxed warning, pancreatitis monitoring, gastroparesis class-action posture), compounded-tirzepatide enforcement (FDA removed tirzepatide from the shortage list in late 2024, triggering ongoing 503A/503B compounder litigation), and pricing pressure under the Medicare drug price negotiation framework expanding through 2026 and beyond.
Brand-specific exposure: tirzepatide concentration risk — a single molecule drives the majority of growth and the majority of equity story. Manufacturing or safety disruption to tirzepatide is the single largest reputational and financial exposure on the Lilly map. Kisunla's commercial reception in Alzheimer's, where the anti-amyloid class faces sustained efficacy and ARIA-safety questioning, is the secondary risk surface.
Frequently Asked Questions
What is Eli Lilly?
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana. Founded 1876. The world's largest pharma company by market capitalization. Best known in 2026 for Mounjaro and Zepbound — both formulations of tirzepatide — and for leading the GLP-1 / incretin category.
Who owns Eli Lilly?
Eli Lilly is a publicly traded company on the New York Stock Exchange under ticker LLY. The largest single shareholder is the Lilly Endowment, a private philanthropic foundation established by the Lilly family in 1937 that holds approximately 10% of outstanding shares.
Who is the CEO of Eli Lilly?
David A. Ricks has served as Chair and Chief Executive Officer since 2017.
What is the difference between Mounjaro and Zepbound?
Same molecule, different label. Both are tirzepatide. Mounjaro is FDA-approved for Type 2 diabetes (May 2022). Zepbound is FDA-approved for chronic weight management (November 2023). The clinical formulation is identical.
Why does Eli Lilly rank #1 in AI engine retrieval for GLP-1 queries?
Market leadership combined with regulatory source-of-record status, sustained business-media coverage, dense Reddit and patient-forum discussion, and tirzepatide's category-defining clinical efficacy. The citation moat is structural and difficult for competitors to close.
Is Eli Lilly bigger than Novo Nordisk?
Yes, by market capitalization, in the modern AI Communications era. The two companies hold a structural duopoly across the GLP-1 / incretin category. Lilly leads on tirzepatide; Novo leads on semaglutide (Ozempic, Wegovy).
